دورية أكاديمية
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
| العنوان: | Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. |
|---|---|
| المؤلفون: | Nabergoj M; Hematology Service, Institut Central des Hôpitaux (ICH), Hôpital du Valais, Sion, Switzerland. mitja.nabergoj@hopitalvs.ch., Eikema DJ; EBMT Statistical Unit, Leiden, The Netherlands., Koster L; EBMT Leiden Study Unit, Leiden, The Netherlands., Platzbecker U; Medical Clinic and Policinic 1, Leipzig, Germany., Sockel K; Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Finke J; University of Freiburg, Freiburg, Germany., Kröger N; Department for Stem Cell Transplantation, University Medical Center Hamburg, Hamburg, Germany., Forcade E; CHU Bordeaux, Pessac, France., Nagler A; Chaim Sheba Medical Center, Tel-Hashomer, Israel., Eder M; Hannover Medical School, Hannover, Germany., Tischer J; Klinikum Grosshadern, Munich, Germany., Broers AEC; Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Kuball J; University Medical Centre, Utrecht, The Netherlands., Wilson KMO; University Hospital of Wales, Cardiff, UK., Hunault-Berger M; CHRU, Angers, France., Collin M; Adult HSCT unit, Newcastle, UK., Russo D; Unit of Bone Marrow Transplantation, University of Brescia, ASST Spedali Civili, Brescia, Italy., Corral LL; Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain., Helbig G; Silesian Medical Academy, Katowice, Poland., Mussetti A; Institut Català d'Oncologia-Hospital Duran i Reynals, Barcelona, Spain., Scheid C; University of Cologne, Cologne, Germany., Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133, Rome, Italy.; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Raj K; Department of Haematology, University College London Hospitals NHS Trust, London, UK., Drozd-Sokolowska J; University Clinical Centre, Medical University of Warsaw, Warsaw, Poland., Yakoub-Agha I; CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France., Robin M; Hopital Saint- Louis, APHP, Université de Paris Cité, Paris, France., McLornan DP; Department of Haematology, University College London Hospitals NHS Trust, London, UK. |
| المصدر: | Bone marrow transplantation [Bone Marrow Transplant] 2024 Mar; Vol. 59 (3), pp. 395-402. Date of Electronic Publication: 2024 Jan 09. |
| نوع المنشور: | Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2003->: London : Nature Publishing Group Original Publication: Basingstoke, Hampshire : Scientific & Medical Division, Macmillan Press, c1986- |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute*/therapy , Lymphoma*/etiology , Lymphoma*/therapy , Neoplasms, Second Primary*/etiology , Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*/etiology, Humans ; Middle Aged ; Retrospective Studies ; Recurrence ; Transplantation Conditioning |
| مستخلص: | Therapy-related myeloid neoplasms (t-MN), either myelodysplastic neoplasms (t-MDS) or acute myeloid leukemias (t-AML), have a poor prognosis and allogeneic haematopoietic cell transplantation (allo-HCT) represents the only curative option. In this multicenter, registry-based study, we analyzed outcomes of 378 patients undergoing first allo-HCT between 2006-2017 for t-MN arising secondary to lymphoma treatment. Median age was 58 years at allo-HCT; 222 (59%) had a diagnosis of t-MDS and 156 (41%) of t-AML, respectively. At the time of allo-HCT, 46% of t-MN cases were reported as in complete remission (CR) and 15% of lymphomas were recorded as not in remission. A reduced intensity conditioning regimen was used in 70% of cases. For the entire cohort, 5-year OS, and t-MN PFS, relapse incidence and NRM were 32%, 28%, 35% and 37%, respectively. In multivariable analysis, undergoing allo-HCT with t-MN not in CR and older age were associated with significantly worse OS, PFS and NRM. At 5 years post allo-HCT, the relapse incidence of lymphoma was low at 3%, while the rate of secondary malignancies was 8%. This analysis shows the curative potential of allo-HCT for patients with t-MN arising secondary to lymphoma treatment in approximately a third of patients. (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.) |
| References: | Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405. (PMID: 10.1182/blood-2016-03-64354427069254) Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. (PMID: 10.1182/blood.202201686735797463) Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28. (PMID: 10.1182/blood.2022015850357678979479031) Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. (PMID: 10.1038/s41375-022-01613-1357328319252913) Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022;57:1217–39. (PMID: 10.1038/s41409-022-01691-w355899979119216) Morton LM, Curtis RE, Linet MS, Schonfeld SJ, Advani PG, Dalal NH, et al. Trends in risk for therapy-related myelodysplastic syndrome/acute myeloid leukemia after initial chemo/immunotherapy for common and rare lymphoid neoplasms, 2000–2018. eClinicalMedicine. 2023;61:102060. (PMID: 10.1016/j.eclinm.2023.1020603745711210344829) Eichenauer DA, Thielen I, Haverkamp H, Franklin J, Behringer K, Halbsguth T, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014;123:1658–64. (PMID: 10.1182/blood-2013-07-51265724478403) Radivoyevitch T, Dean RM, Shaw BE, Brazauskas R, Tecca HR, Molenaar RJ, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018;74:130–6. (PMID: 10.1016/j.leukres.2018.07.016300558226219911) Bachiashvili K, Francisco L, Chen Y, Bosworth A, Forman SJ, Bhatia R, et al. Peripheral blood parameter abnormalities precede therapy‐related myeloid neoplasms after autologous transplantation for lymphoma. Cancer. 2022;128:1392–401. (PMID: 10.1002/cncr.3407234962652) Joelsson J, Wästerlid T, Rosenquist R, Jakobsen LH, El-Galaly TC, Smedby KE, et al. Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study. Blood Adv. 2022;6:2657–66. (PMID: 10.1182/bloodadvances.2021006369350422399043935) Moreno Berggren D, Garelius H, Willner Hjelm P, Nilsson L, Rasmussen B, Weibull CE, et al. Therapy-related MDS dissected based on primary disease and treatment—a nationwide perspective. Leukemia. 2023;37:1103–12. (PMID: 10.1038/s41375-023-01864-63692800810169633) Alkhateeb HB, Mohty R, Greipp P, Bansal R, Hathcock M, Rosenthal A, et al. Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for non-hodgkin lymphoma. Blood Cancer J. 2022;12:113. (PMID: 10.1038/s41408-022-00707-4358828449325766) Carreras E, Dufour C, Mohty M, Kröger N, editors. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Cham: Springer International Publishing; 2019. https://doi.org/10.1007/978-3-030-02278-5 . Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2009;15:1628–33. (PMID: 10.1016/j.bbmt.2009.07.004) Robin M, De Wreede LC, Schroeder T, Stölzel F, Kröger N, Koster L, et al. Primary cancer matters in therapy-related myeloid neoplasm patients receiving allogeneic hematopoietic cell transplantation: a Study From the Chronic Malignancies Working Party of the EBMT. HemaSphere. 2023;7:e851. (PMID: 10.1097/HS9.0000000000000851368914559988287) Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, et al. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022;57:1072–8. (PMID: 10.1038/s41409-022-01686-735459878) Robin M, Wang J, Koster L, Beelen DW, Bornhäuser M, Kroeger N, et al. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in patients with therapy-related myeloid neoplasm: a study from the Chronic Malignancies Working Party of the EBMT. Blood. 2019;134:45–5. (PMID: 10.1182/blood-2019-124765) Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant. 2020;55:224–32. (PMID: 10.1038/s41409-019-0673-331527819) Wenge DV, Wethmar K, Mikesch J-H, Reicherts C, Schliemann C, Mesters R, et al. Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. Leuk Lymphoma. 2021;62:1930–9. (PMID: 10.1080/10428194.2021.189464533779471) Jaimes-Albornoz D, Mannone L, Nguyen-Quoc S, Chalandon Y, Chevallier P, Mohty M, et al. Allogeneic stem cell transplantation in therapy-related myelodysplasia after autologous transplantation for lymphoma: a retrospective study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019;25:2366–74. (PMID: 10.1016/j.bbmt.2019.07.01331326611) Kroger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica. 2009;94:542–9. (PMID: 10.3324/haematol.2008.000927192789682663618) Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119:6145–54. (PMID: 10.1182/blood-2011-12-395970225630893383022) Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, et al. Allogeneic Transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021. https://doi.org/10.1016/j.jtct.2021.08.010 . Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, et al. Comparative outcomes of myeloablative and reduced‐intensity conditioning allogeneic hematopoietic cell transplantation for therapy‐related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation. Am J Hematol. 2019;94:431–8. (PMID: 10.1002/ajh.2539530597620) Lawless S, Morris C, Eikema D-J, Kostner L, Stoelzel F, Kröger N, et al. Outcomes of allogeneic haematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment for myeloma. Blood. 2022;140:4884–5. (PMID: 10.1182/blood-2022-169326) Minetto P, Guolo F, Clavio M, Kunkl A, Colombo N, Carminati E, et al. Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. Br J Haematol. 2019;184:457–60. (PMID: 10.1111/bjh.1510629359798) Press RD, Eickelberg G, Froman A, Yang F, Stentz A, Flatley EM, et al. Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. Am J Hematol. 2019;94:902–12. (PMID: 10.1002/ajh.2551431124175) Hoffmann AP, Besch AL, Othus M, Morsink LM, Wood BL, Mielcarek M, et al. Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2020;55:669–72. (PMID: 10.1038/s41409-019-0739-231685932) Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, et al. Prognostic value of measurable residual disease in patients with AML undergoing HSCT: a multicenter study. Cancers. 2023;15:1609. (PMID: 10.3390/cancers150516093690040010000405) |
| تواريخ الأحداث: | Date Created: 20240110 Date Completed: 20240311 Latest Revision: 20240311 |
| رمز التحديث: | 20240311 |
| DOI: | 10.1038/s41409-023-02193-z |
| PMID: | 38195984 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1476-5365 |
|---|---|
| DOI: | 10.1038/s41409-023-02193-z |